Article-Journal

Low-dose CT for MRI-free quantification of tau PET in Alzheimer's disease: a multicentre, cross-sectional, comparison study

Tau PET quantification typically requires structural MRI for reference-region definition, normalisation, and segmentation, which imposes a logistical and operational burden. In …

Guilherme Povala

CSF total tau as a proxy of synaptic degeneration

Cerebrospinal fluid (CSF) total tau (t-tau) is considered a biomarker of neuronal degeneration alongside brain atrophy and fluid neurofilament light chain protein (NfL) in …

Carolina Soares

Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease

BACKGROUND: Clinical trials have recently incorporated plasma glial fibrillary acidic protein (GFAP) as an exploratory endpoint. To include plasma GFAP as a secondary endpoint, it …

Sarah Abbas

Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer's disease

Previous studies suggest glial and neuronal changes may trigger synaptic dysfunction in Alzheimer's disease (AD), but the link between their markers and synaptic abnormalities in …

Francieli Rohden

Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease

INTRODUCTION: Cognitively unimpaired (CU) amyloid beta (Aβ)+ individuals with elevated plasma glial fibrillary acidic protein (GFAP) have an increased risk of Alzheimer's disease …

Bruna Bellaver

Impact of the polygenic risk scores for attention-deficit/hyperactivity disorder in Alzheimer's disease

INTRODUCTION: Epidemiological studies indicate a link between attention-deficit/hyperactivity disorder (ADHD) and elevated risk of dementia. However, the impact of ADHD on …

Douglas Teixeira Leffa